News

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO.

“We are excited to welcome Dave to our leadership team,” said McCoy. “His deep expertise in pharmaceutical manufacturing and global operations will be instrumental as we continue to bring our Petersburg facility online and expand access to essential medicines.”

Sehgal has nearly 30 years of experience in the pharmaceutical industry, having held leadership roles in the vaccines, biologics and small molecule manufacturing space. He also has significant experience in technical services, quality and process development. Dr. Sehgal succeeds Jay Benson.

“I am thrilled to join Civica at this time in the company’s history,” said Sehgal. “I look forward to leading the team that will bring high-quality, essential generic medicines, manufactured in the United Sates to patients who need them.”

Dr. Sehgal resides in Raleigh, NC and will be working closely with the Civica team at the company’s manufacturing facility in Petersburg, Va. The 140,000 square foot, state-of-the-art facility currently employs more than 200 skilled workers, with plans to hire another 60 employees by the end of 2025. The facility has the capacity to manufacture 90 million vials, 50 million syringes and 120 million pre-filled pens of generic sterile injectable medicines every year. The facility is in the final stages of certification by regulatory authorities and will be producing medicines for distribution in 2026.

Prior to joining Civica, Dr. Sehgal was the Vice President and Global Processing Engineering Head at CSL-Behring in Holly Springs, North Carolina. In that role, he led a team of 500 scientists and engineers across four global sites in support of all CSL-Behring products. Before CSL-Behring, Sehgal held leadership positions at FUJIFILM Diosynth Biotechnologies, Seqirus, Novartis, and Merck. Sehgal earned a bachelor’s, master’s, and doctoral degree in chemical engineering from NC State University.

This appointment reflects Civica’s continued commitment to operational excellence and its mission to make quality generic medicines accessible and affordable for all.

 

Read more here.

Recent News

07/14/2026

ARPA-H awards up to $160 million to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, today announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program — a critical investment toward bringing new treatments to patients faster and cure rare genetic pediatric diseases. THRIVE

07/09/2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for QRX003 for the treatment of Peeling Skin Syndrome (PSS), enabling initiation of its planned Phase 2 clinical study. Quoin

07/07/2026

United Therapeutics Corporation Acquires Thymmune Therapeutics

United Therapeutics Corporation (Nasdaq: UTHR) announced it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the